| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Taysha Gene Therapies, Inc. | 18,670,089 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Venrock Healthcare Capital Partners III, L.P. | Taysha Gene Therapies, Inc. | 10,412,872 | 5.6% | EDGAR |
| SC 13G | 2024-02-14 | RTW INVESTMENTS, LP | Taysha Gene Therapies, Inc. | 18,505,556 | 9.8% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | Taysha Gene Therapies, Inc. | 22,439,124 | 12.0% | EDGAR |
| SC 13G/A | 2024-02-09 | TCG Crossover GP I, LLC | Taysha Gene Therapies, Inc. | 2,912,861 | 1.6% | EDGAR |
| SC 13G/A | 2023-09-11 | FMR LLC | Taysha Gene Therapies, Inc. | 27,973,546 | 15.0% | EDGAR |
| SC 13G | 2023-08-28 | Venrock Healthcare Capital Partners III, L.P. | Taysha Gene Therapies, Inc. | 14,444,444 | 7.7% | EDGAR |
| SC 13G | 2023-08-25 | RA CAPITAL MANAGEMENT, L.P. | Taysha Gene Therapies, Inc. | 18,690,868 | 10.0% | EDGAR |
| SC 13G | 2023-08-25 | TCG Crossover GP I, LLC | Taysha Gene Therapies, Inc. | 11,111,111 | 5.9% | EDGAR |
| SC 13D/A | 2023-08-21 | Manning Paul B | Taysha Gene Therapies, Inc. | 23,476,333 | 12.6% | EDGAR |
| SC 13D/A | 2023-08-18 | Astellas Pharma Inc. | Taysha Gene Therapies, Inc. | 7,266,342 | 3.9% | EDGAR |
| SC 13G/A | 2023-02-09 | FMR LLC | Taysha Gene Therapies, Inc. | 3,204,922 | 5.1% | EDGAR |
| SC 13G/A | 2022-11-10 | FMR LLC | Taysha Gene Therapies, Inc. | 3,274,557 | 6.0% | EDGAR |
| SC 13D/A | 2022-11-02 | Manning Paul B | Taysha Gene Therapies, Inc. | 6,989,861 | 11.2% | EDGAR |
| SC 13D | 2022-10-31 | Audentes Therapeutics, Inc. | Taysha Gene Therapies, Inc. | 7,266,342 | 11.6% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | Taysha Gene Therapies, Inc. | 1,046,490 | 2.6% | EDGAR |
| SC 13G/A | 2022-02-09 | FMR LLC | Taysha Gene Therapies, Inc. | 4,280,494 | 11.1% | EDGAR |
| SC 13G/A | 2022-02-07 | BlackRock Inc. | Taysha Gene Therapies, Inc. | 3,032,963 | 7.9% | EDGAR |
| SC 13G | 2021-09-24 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | Taysha Gene Therapies, Inc. | 1,156,255 | 3.0% | EDGAR |
| SC 13G | 2021-02-16 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO | Taysha Gene Therapies, Inc. | 2,179,000 | 5.8% | EDGAR |